OKYO Pharma Limited
OKYO
$-0.03
Change (1 day)
$2.12
Year High
$0.81
Year Low
Categories
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
OKYO Pharma Limited (OKYO) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2024 | 580.94 K | -826,848 | 7.42 M | 1.54 M | 1.54 M |
| 2023 | -1,830,270 | 7.26 M | 5.2 M | 5.2 M | |
| 2022 | -2,700,724 | 1.35 M | 4.3 M | 4.3 M | |
| 2021 | -6,790,569 | 1.77 M | 7.09 M | 6.99 M | |
| 2020 | 326.22 K | -203,339 | 737.2 K | 597.4 K | 566.73 K |